What is BioRestorative Therapies's market cap?

BioRestorative Therapies (BRTX) has a market capitalization of $7.1M and trades on NASDAQ.

Who are BioRestorative Therapies's competitors?

BioRestorative Therapies's key competitors include Eli Lilly, Pfizer, Creative Medical Technology Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does BioRestorative Therapies partner with?

BioRestorative Therapies's notable partners include Regenerative Sciences, LLC, Northwell Health, PRC Clinical, and others.

Where is BioRestorative Therapies headquartered?

BioRestorative Therapies is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 1997.

BioRestorative Therapies

BRTX

BioRestorative Therapies is a clinical-stage biotechnology company focused on developing regenerative medicine products using adult stem cell and tissue protocols.

Market cap

$7.06M-36.5%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$23.2KMiss by $289.3K EPS-$0.19Beat by $0.01

Read the full report

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$600.0K

EPS estimate-$0.15

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Pfizer$140.61B+1.7%

Orthofix Medical Inc.$481.0M+7.7%

OSR Holdings, Inc.$15.2M-18.6%

BCD

BioCardia, Inc.$12.0M-4.8%

BioRestorative Therapies$7.1M-40.1%

Soligenix, Inc.$5.4M+28.4%

Creative Medical Technology Holdings, Inc.$5.1M-24.7%

By revenue growth

Eli Lilly+47.4%

Orthofix Medical Inc.+2.6%

Pfizer+1.4%

By net margin

Eli Lilly34.99%+12.3pp

Pfizer15.65%+6.3pp

Orthofix Medical Inc.-7.27%+10.5pp

Profile

BioRestorative Therapies is a clinical-stage biotechnology company focused on developing regenerative medicine products using adult stem cell and tissue protocols. The company's core value proposition lies in its proprietary cell-based therapies for treating chronic disc-related pain and metabolic disorders like obesity and type 2 diabetes.

Competitive position

BioRestorative Therapies is a clinical-stage innovator in the autologous stem cell space, currently advancing a Phase 2 trial for its lead candidate with Fast Track designation from the FDA.

GeographiesUnited States

Customer segmentsMedical Professionals, Healthcare Institutions, Aesthetic Clinics, Consumers

Business modelResearch and Development, Licensing, Direct-to-Consumer, Contract Manufacturing

SuppliersBone marrow and adipose tissue donors, Cell culture media and reagent suppliers, Laboratory equipment manufacturers, Third-party contract research organizations

CustomersSpecialized medical practitioners, Hospitals, Medical spas, Biotechnology strategic partners

CountryUnited States of America

Listed1997

Employees11.0

CEOLance Alstodt

SectorHealthcare

IndustryBiotechnology

Websitebiorestorative.com

FilingsSEC EDGAR

Questions, answered.

What is BioRestorative Therapies's market cap?: BioRestorative Therapies (BRTX) has a market capitalization of $7.1M and trades on NASDAQ.
Who are BioRestorative Therapies's competitors?: BioRestorative Therapies's key competitors include Eli Lilly, Pfizer, Creative Medical Technology Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does BioRestorative Therapies partner with?: BioRestorative Therapies's notable partners include Regenerative Sciences, LLC, Northwell Health, PRC Clinical, and others.
Where is BioRestorative Therapies headquartered?: BioRestorative Therapies is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 1997.